Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for ALX2004 in EGFR-expressing solid tumors. The expected timing is based on the latest available company guidance and may change.
4/7/25- IND cleared. 8/19/25- Trial initiated. 10/23/25– Presented preclinical data & trial design at AACR-NCI-EORTC’25. Initial safety data expected H1 2026. 11/07/25:- Phase 1 dose escalation cleared 1 mg/kg cohort, enrolling 2 mg/kg; initial safety data still expected H1 2026. 01/08/26:- Third dose cohort at 4mg/kg initiated; no DLTs; initial safety data still expected H1 2026. 02/27/26:- Phase 1 ALX2004 enrolling third 4 mg/kg cohort; dose-escalation safety data timing updated to H2 2026. 05/08/26:- Phase 1 ALX2004 dose-escalation enrolling well; safety data still expected in H2 2026. 08/06/26:- Phase 1 enrollment continues; initial safety data remains on track for H2 2026.
Verification
Confirm timing and program details against the company announcement or filing.